Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06921759 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis
A Phase 3 study of Atopic Hand and Foot Dermatitis, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 206
- Enrollment target
- 20
- Study locations
NCT06921759: Active Phase 3 study of Atopic Hand and Foot Dermatitis, sponsored by Eli Lilly and Company.
NCT06921759 is a Phase 3 study of Atopic Hand and Foot Dermatitis that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 206 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06921759, a Phase 3 study of Atopic Hand and Foot Dermatitis, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 206 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with atopic hand and foot dermatitis. This study lasts up to 32 weeks, including a 6-week screening period, a 16-week treatment period, and a safety follow-up visit 12 weeks after the last dose.
Primary Outcome
The HF-IGA is an assessment scale used to determine the severity of hand and foot atopic dermatitis (AD) and clinical response to treatment on a 5-point scale, 0 (clear) to 4 (severe). Higher scores indicate more disease severity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lebrikizumab
Study Locations (20)
Other
- CONEXA Investigacion Clinica S.A. - Buenos Aires
- Investigaciones Medicas Imoba Srl - Buenos Aires
- CIPREC - Buenos Aires
- Instituto de Neumonologia Y Dermatologia - Buenos Aires
- Psoriahue - Buenos Aires
- Fundación Respirar - Buenos Aires
Florida
- Encore Medical Research - Hollywood
- Research Associates of South Florida - Miami - Southwest 8th Street - Miami
- Renstar Medical Research - Ocala
Texas
- Progressive Clinical Research - San Antonio
- Texas Dermatology and Laser Specialists - San Antonio
- Complete Dermatology - Sugar Land
California
- First OC Dermatology Research Inc - Fountain Valley
- Dermatology Research Associates - Los Angeles
Illinois
- DeNova Research - Chicago
Indiana
- Southern Indiana Clinical Trials - New Albany
Michigan
- Revival Research Institute, LLC - Troy
Missouri
- MediSearch Clinical Trials - Saint Joseph
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2025-04-21 |
| Est. Completion | 2026-09 |
| Phase | Phase 3 |
What the registry record for NCT06921759 still lists
NCT06921759 is an interventional study that assigns participants to a tested intervention. The registered 206 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Atopic Hand and Foot Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06921759 names 20 study sites across 10 states, led by Other, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT06921759 about?
NCT06921759 is a clinical study titled "A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis". The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with atopic hand and foot dermatitis. This study lasts up to 32 weeks, including a 6-week screening period, a 16-week treatment period, and a safety follow-u...
What is the current status of trial NCT06921759?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 206 participants. The study started on 2025-04-21. Estimated completion is 2026-09.
What conditions does trial NCT06921759 study?
This clinical trial studies the following conditions: Atopic Hand and Foot Dermatitis.
What interventions are being tested in trial NCT06921759?
The interventions under investigation include: Placebo (DRUG), Lebrikizumab (DRUG).
Who is sponsoring clinical trial NCT06921759?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06921759 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06921759's enrollment target sits among peer trials
206 1348th of 2000 higher than 651 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03373968 · 206 participants · Phase 2
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- NCT03550391 · 206 participants · Phase 3
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- NCT04757116 · 206 participants · NA
Post-Market Study to Assess iTind Safety in Comparison to UroLift
- NCT05675865 · 206 participants · NA
Cryoablation for Monomorphic Ventricular Tachycardia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI